Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

DHT is important for sexual function and mood, but finasteride and dutasteride can reduce DHT, causing side effects like reduced libido and erectile dysfunction. These treatments are effective for hair loss, but their impact on DHT leads to debate.

A 57-year-old man with male pattern hair loss and insulin resistance experienced hair regrowth and weight loss after using tirzepatide, without other hair treatments. Dysregulated glucose metabolism is linked to hair loss, with tirzepatide potentially improving hair density by normalizing insulin resistance.

A 23-year-old man uses a topical spray with minoxidil, finasteride, and tretinoin for hair loss, experiencing improved hair growth but occasional heart palpitations. He worries his girlfriend might leave him if he goes bald, but commenters advise that if she would leave over hair loss, she isn't worth it.

A user is experiencing hairline recession and has started using RU58841, applying it to the temples. They are seeking advice on the appropriate dosage for this specific area.

A 24-year-old male experienced significant hair regrowth over 7 months using Kirkland's 5% topical minoxidil foam twice daily, attributing initial hair loss to stress rather than male pattern baldness. Despite suggestions to add a DHT blocker like finasteride, he remains cautious due to concerns about potential effects on beard growth.

The conversation discusses whether curly hair affects hair transplant outcomes, with advice to consult a specialist experienced with curly hair. The donor area's suitability is questioned, noting curly hair might appear thicker.

Applying minoxidil with long hair can be challenging due to its oily appearance, but users suggest methods like using a topical applicator, parting hair, or applying to damp hair. Some prefer oral minoxidil for ease, while others use foam or adjust application techniques to target the scalp effectively.

A user is experiencing hair regrowth after using oral finasteride, topical minoxidil, biotin, multivitamins, vitamin D, and dutasteride. They also use ketoconazole shampoo and Revita density shampoo to manage flakes and improve hair thickness.

Dutasteride is praised for improving skin and hair regrowth, with fewer side effects than finasteride. Users report mixed results on shedding and regrowth, with some experiencing enhanced libido and skin quality.

A user shared their experience with a hair transplant, emphasizing the importance of avoiding caffeine 7 days before the procedure. Ignoring this advice led to reduced effectiveness of the numbing agent, causing significant discomfort during the transplant.

Finasteride and minoxidil have helped maintain hair density and possibly improved coverage, though results vary and regrowth can take time. Some suggest trying dutasteride and oral minoxidil for more significant regrowth.

A 32-year-old man experienced positive hair regrowth after 4 months using 1.2mg finasteride and 3mg oral minoxidil, with no side effects. He used a chewable combo pill from Hims, noting minoxidil aids regrowth and finasteride maintains hair.

A 25-year-old male has been using 0.5mg dutasteride and 5mg minoxidil for 1.6 years to treat diffuse thinning, with significant hair regrowth except for the hairline. He plans to get a hair transplant for further improvement and reports no side effects from the treatment.

A pharmacy student proposed a hair loss treatment using minoxidil, finasteride, clascoterone, and tretinoin, aiming for high effectiveness with minimal side effects. Reactions were mixed, with some questioning its feasibility and others showing interest.

Creatine may cause hair loss in some individuals, especially those on finasteride, despite no scientific link. Personal experiences suggest individual sensitivity to DHT could be a factor.

A user experienced significant hair regrowth using finasteride 1 mg daily for two years and gradually introduced dutasteride 0.5 mg daily over four months. They reported no side effects and plan to switch fully to dutasteride due to its cost-effectiveness and potential effectiveness.

An 18-year-old is using a high-dose hair loss treatment with 40mg daily dutasteride, finasteride, minoxidil, tretinoin, and topical bicalutamide. Despite health risk concerns, especially liver issues, they report hair regrowth progress and intend to continue the regimen.

Significant hair regrowth was achieved after six months using finasteride and minoxidil, with no side effects reported. The user plans to taper off minoxidil and is considering oral minoxidil, but is cautious due to potential heart issues.

PTD-DBM is being explored for hair regrowth by targeting CXXC5, with clinical trials expected after pre-clinical studies. Users express anticipation and skepticism about its effectiveness.

RU58841 shows the strongest results despite weaker binding affinity, while KX-826 and CB-03-01 are more expensive and have minimal side effects. RU58841 is considered effective but has potential health risks if ingested; users report positive outcomes with RU58841 and finasteride.

The user experienced reduced hair loss using an online serum but found it too expensive and is seeking a vendor for ptd-dbm. They are also interested in KY19382 but are unable to find it.

The conversation is about selling KY19382 powder, a novel activator of Wnt/β-catenin signaling, and Kolliphor EL liquid for vehicle formulation. The seller offers worldwide shipping.

A user applied the 8T3 product for hair loss, targeting LPP and AGA, and plans to update on its effectiveness. The product uses a saline buffered phosphate vehicle, suitable for those intolerant to ethanolic vehicles.

SCUBE3, a protein linked to hair growth in moles, was discovered over 25 years ago and is being developed by Amplifica for potential hair loss treatment. Concerns exist about SCUBE3's association with cancer, as it is a protein that promotes cell growth, which could potentially trigger cancer development if used for hair growth therapy.

PTD-DBM is a Korean-developed treatment for hair loss, with limited information available and some users testing it personally. A user purchased PTD-DBM for $115 and plans to test it on their temples, but its effectiveness and authenticity remain uncertain.

Oral PTD-DBM was discussed as a potential hair loss treatment, but it was deemed ineffective in humans despite promising results in mice. The conversation concluded that trying it without VPA might be unwise.

PTD-DBM therapy for hair loss is being developed by Dr. Kang-Yell Choi, with human testing planned in South Korea. Some clinics in the U.S. offer PTD-DBM/valproic acid therapy, but it hasn't completed trials yet.

MCL-1 protein may help maintain hair follicles in the growth phase and prevent miniaturization. There is interest in experimental treatments like exosomes, peptides, or stem cell serums to upregulate MCL-1 for hair loss, especially for those not using minoxidil or finasteride.

GT20029 and pyrilutamide are both androgen antagonists but work differently; GT20029 degrades the androgen receptor, while pyrilutamide blocks DHT from binding. GT20029 is expected to have similar efficacy to CosmeRNA.

CB-03-01 is considered too costly and lacks a proper delivery method, making it less viable compared to RU58841, which has shown effectiveness with minimal side effects. Finasteride caused a drop in libido for one user.